aTyr Pharma (NASDAQ:LIFE) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. They currently have $4.50 price objective on the biotechnology company’s stock.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

Separately, Oppenheimer reissued a buy rating on shares of aTyr Pharma in a report on Tuesday, September 22nd. Five investment analysts have rated the stock with a buy rating, aTyr Pharma has a consensus rating of Buy and a consensus price target of $10.13.

aTyr Pharma stock opened at $3.94 on Wednesday. The business’s fifty day simple moving average is $4.11 and its two-hundred day simple moving average is $3.89. aTyr Pharma has a 12 month low of $2.13 and a 12 month high of $7.27. The company has a market capitalization of $40.13 million, a price-to-earnings ratio of -1.48 and a beta of 2.14.

aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Tuesday, November 17th. The biotechnology company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.06. aTyr Pharma had a negative return on equity of 52.75% and a negative net margin of 202.02%. The business had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.16 million. On average, equities analysts expect that aTyr Pharma will post -2.14 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Two Sigma Advisers LP raised its stake in shares of aTyr Pharma by 122.7% in the 2nd quarter. Two Sigma Advisers LP now owns 80,950 shares of the biotechnology company’s stock valued at $359,000 after purchasing an additional 44,600 shares in the last quarter. Ardsley Advisory Partners LP acquired a new stake in shares of aTyr Pharma in the 3rd quarter valued at $65,000. Acadian Asset Management LLC increased its holdings in shares of aTyr Pharma by 22.2% during the 3rd quarter. Acadian Asset Management LLC now owns 83,052 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 15,088 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of aTyr Pharma by 23.8% during the 3rd quarter. BlackRock Inc. now owns 41,411 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 7,948 shares during the last quarter. 56.03% of the stock is currently owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial.

Featured Story: Why Net Income is Important to Investors

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.